Welcome to our dedicated page for Panacea Life Sciences Hldgs news (Ticker: PLSH), a resource for investors and traders seeking the latest updates and insights on Panacea Life Sciences Hldgs stock.
Panacea Life Sciences Holdings reports developments tied to its natural health and wellness business, including manufacturing, research, product development and distribution of plant-based products. Company news has covered nutraceutical, cannabinoid, mushroom, kratom and other natural ingredients and products, as well as CBD/CBG research for irritable bowel symptoms and product formats such as soft gels, liquid fills and topical lotions.
Recurring updates also include retail and distribution expansion through Tampa-area natural health stores, licensing and development arrangements for Sky Wellness-branded CBD and non-CBD products, and the Benivita PLSH venture for direct-to-consumer non-insurance benefits, virtual telemedicine services and lifestyle wellness programs. Coverage also includes governance, shareholder voting, capital-structure and operating-result disclosures.
Panacea Life Sciences, Inc. (OTCQB:PLSH) has partnered with MyPharma2Go to enter Brazil's cannabis market. This collaboration aims to enhance MyPharma2Go's offerings by delivering premium cannabis products. Founded in 2017, MyPharma2Go has supported over 240,000 patients across Brazil. According to their CEO, the partnership aligns with their goal of top-tier service. Panacea's Executive VP, Nick Cavarra, stated that this partnership provides access to Brazil's large consumer base, potentially increasing revenues and shareholder value in 2022.
Panacea Life Sciences Holdings, Inc. (OTCQB:PLSH) announced the closure of a private placement with Lincoln Park Capital Fund, LLC, raising $1 million. The transaction involved a 10% original issue discount senior convertible promissory note worth $1.1 million and warrants to buy 785,715 shares at a $1.40 exercise price. This funding aims to enhance growth strategies and market share for Panacea's cannabinoid products. The company operates a 51,000 square foot facility in Colorado and has secured prior investments totaling $34 million.
Exactus, Inc. (OTCQB:EXDI), soon to be Panacea Life Sciences, Inc. (OTCQB:PLSH), is leveraging the resurgence of air travel at Denver International Airport (DEN), which saw nearly 25 million passengers in the first half of 2021. Panacea is the first company to sell CBD products at DEN, offering over 18 therapeutic products designed to alleviate travel-related discomfort. These products comply with legal standards, containing less than 0.3% THC. Panacea, founded in 2017, has received $20 million in investments and operates a 51,000 sq. ft. certified facility in Colorado.
Exactus, Inc. (OTCQB:EXDI), soon to be Panacea Life Sciences, Inc. (OTCQB:PLSH), is leveraging the resurgence of passenger traffic at Denver International Airport to promote its premium CBD products, with nearly 25 million travelers in the first half of 2021. Panacea has established two kiosk locations in the airport, making it the first company to offer CBD products directly to passengers. The range includes topical CBD items for pain relief, adhering to hemp regulations. Founded in 2017, Panacea has attracted $20 million in investments, continuing to grow in the evolving CBD market.